Effective Killing of Cancer Cells Through ROS-Mediated Mechanisms by AMRI-59 Targeting Peroxiredoxin i

Antioxidants and Redox Signaling

Volumn 24, Issue 8, 2016, Pages 453-469

  Yang, Yeon Ju ^a,b   Baek, Jin Young ^a   Goo, Jail ^c   Shin, Yoonho ^d   Park, Jong Kuk ^e   Jang, Ji Yong ^a   Wang, Su Bin ^a   Jeong, Woojin ^a   Lee, Hwa Jeong ^a   Um, Hong Duck ^e   Lee, Sang Kook ^d   Choi, Yongseok ^c   Rhee, Sue Goo ^f   Chang, Tong Shin ^a  

^a Ewha Womans University   (South Korea)

^b Yonsei University   (South Korea)

^c Korea University   (South Korea)

^d Seoul National University   (South Korea)

^e Korea Institute of Radiation and Medical Science   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMRI 59; ANTINEOPLASTIC AGENT; APOPTOSIS SIGNAL REGULATED KINASE 1; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PEROXIREDOXIN 1; PROTEIN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ACETOPHENONE DERIVATIVE; AMRI-59; ENZYME INHIBITOR; MOLECULAR LIBRARY; PEROXIREDOXIN; PIPERIDINE DERIVATIVE;

A549 CELL LINE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C57BL/6N MOUSE; CATALYSIS; CELL DEATH; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PREMEDICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT CHANGE; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; TUMOR CELL LINE;

ACETOPHENONES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; PEROXIREDOXINS; PIPERIDINES; REACTIVE OXYGEN SPECIES; SMALL MOLECULE LIBRARIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962589825     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.6187     Document Type: Article

References (76)

1. Adachi Y, Shibai Y, Mitsushita J, Shang WH, Hirose K, and Kamata T. Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 27: 4921-4932, 2008.
2. Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy S, Petros JA, and Lambeth JD. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA 98: 5550-5555, 2001.
3. Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, and Rhee SG. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 272: 217-221, 1997.
4. Baek JY, Han SH, Sung SH, Lee HE, Kim YM, Noh YH, Bae SH, Rhee SG, and Chang TS. Sulfiredoxin protein is critical for redox balance and survival of cells exposed to low steady-state levels of H2O2. J Biol Chem 287: 81-89, 2012.
5. Bienert GP, Schjoerring JK, and Jahn TP. Membrane transport of hydrogen peroxide. Biochim Biophys Acta 1758: 994-1003, 2006.
6. Biteau B, Labarre J, and Toledano MB. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature 425: 980-984, 2003.
7. Brigelius-Flohé R and Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta 1790: 1555-1568, 2009.
8. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 18: 775-794, 1995.
9. Cha MK, Suh KH, and Kim IH. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res 28: 93, 2009.
10. Chae HZ, Kim HJ, Kang SW, and Rhee SG. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res Clin Pract 45: 101-112, 1999.
11. Chang JW, Jeon HB, Lee JH, Yoo JS, Chun JS, Kim JH, and Yoo YJ. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 289: 507-512, 2001.
12. Chang TS, Cho CS, Park S, Yu S, Kang SW, and Rhee SG. Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem 279: 41975-41984, 2004.
13. Chen MF, Keng PC, Shau H, Wu CT, Hu YC, Liao SK, and Chen WC. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 64: 581-591, 2006.
14. Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR, and Kim JR. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22: 3331-3335, 2002.
15. Chung-man Ho J, Zheng S, Comhair SA, Farver C, and Erzurum SC. Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res 61: 8578-8585, 2001.
16. D'Autreaux B and Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8: 813-824, 2007.
17. Fang J, Nakamura H, and Iyer AK. Tumor-targeted induction of oxystress for cancer therapy. J Drug Target 15: 475-486, 2007.
18. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 15: 247-254, 2003.
19. Fujino G, Noguchi T, Matsuzawa A, Yamauchi S, Saitoh M, Takeda K, and Ichijo H. Thioredoxin and TRAF family proteins regulate reactive oxygen species-dependent activation of ASK1 through reciprocal modulation of the Nterminal homophilic interaction of ASK1. Mol Cell Biol 27: 8152-8163, 2007.
20. Groeger G, Quiney C, and Cotter TG. Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal 11: 2655-2671, 2009.
21. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, and Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Rastransformed fibroblasts. Science 275: 1649-1652, 1997.
22. Jeong W, Yoon HW, Lee SR, and Rhee SG. Identification and characterization of TRP14, a thioredoxin-related protein of 14 kDa. New insights into the specificity of thioredoxin function. J Biol Chem 279: 3142-3150, 2004.
23. Jin DY, Chae HZ, Rhee SG, and Jeang KT. Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J Biol Chem 272: 30952-30961, 1997.
24. Kalinina EV, Berezov TT, Shtil AA, Chernov NN, Glazunova VA, Novichkova MD, and Nurmuradov NK. Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med 153: 878-881, 2012.
25. Kampkotter A, Wiegand C, Timpel C, Rohrdanz E, Chovolou Y, Kahl R, and Watjen W. Increased expression of catalase in human hepatoma cells by the soy isoflavone, daidzein. Basic Clin Pharmacol Toxicol 102: 437-442, 2008.
26. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, and Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 273: 6297-6302, 1998.
27. Kang SW, Rhee SG, Chang TS, Jeong W, and Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 11: 571-578, 2005.
28. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, and Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 9: 3418-3424, 2003.
29. Kim H, Kim H, Hong S, Rhee SG, and Jeong W. A colorimetric assay for sulfiredoxin activity using inorganic phosphate measurement. Anal Biochem 393: 36-40, 2009.
30. Kim HS, Lee TB, and Choi CH. Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100. Biochem Biophys Res Commun 281: 109-114, 2001.
31. Kim JA, Park S, Kim K, Rhee SG, and Kang SW. Activity assay of mammalian 2-cys peroxiredoxins using yeast thioredoxin reductase system. Anal Biochem 338: 216-223, 2005.
32. Kim SY, Kim TJ, and Lee KY. A novel function of peroxiredoxin 1 (Prx-1) in apoptosis signal-regulating kinase 1 (ASK1)-mediated signaling pathway. FEBS Lett 582: 1913-1918, 2008.
33. Kim YJ, Lee WS, Ip C, Chae HZ, Park EM, and Park YM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res 66: 7136-7142, 2006.
34. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, and Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196: 316-323, 2002.
35. Lee JY, Jung HJ, Song IS, Williams MS, Choi C, Rhee SG, Kim J, and Kang SW. Protective role of cytosolic 2-cys peroxiredoxin in the TNF-alpha-induced apoptotic death of human cancer cells. Free Radic Biol Med 47: 1162-1171, 2009.
36. Lee S-R, Kim J-R, Kwon K-S, Yoon HW, Levine RL, Ginsburg A, and Rhee SG. Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J Biol Chem 274: 4722-4734, 1999.
37. Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, Saily M, and Kinnula VL. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111: 514-521, 2004.
38. Liu CX, Yin QQ, Zhou HC, Wu YL, Pu JX, Xia L, Liu W, Huang X, Jiang T, Wu MX, He LC, Zhao YX, Wang XL, Xiao WL, Chen HZ, Zhao Q, Zhou AW, Wang LS, Sun HD, and Chen GQ. Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat Chem Biol 8: 486-493, 2012.
39. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, and Bast RC, Jr. A Genetically defined model for human ovarian cancer. Cancer Res 64: 1655-1663, 2004.
40. Lu W, Fu Z, Wang H, Feng J, Wei J, and Guo J. Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells' survival by protecting cells from oxidative stress. Mol Cell Biochem 387: 261-270, 2013.
41. Miller EW, Dickinson BC, and Chang CJ. Aquaporin-3 mediates hydrogen peroxide uptake to regulate downstream intracellular signaling. Proc Natl Acad Sci USA 107: 15681-15686, 2010.
42. Mitsushita J, Lambeth JD, and Kamata T. The superoxidegenerating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res 64: 3580-3585, 2004.
43. Neumann CA and Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 7: 375-380, 2007.
44. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, and Chae HZ. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21: 2085-2090, 2001.
45. Nomura K, Imai H, Koumura T, Kobayashi T, and Nakagawa Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase inhibits the release of cytochrome c from mitochondria by suppressing the peroxidation of cardiolipin in hypoglycaemia-induced apoptosis. Biochem J 351: 183-193, 2000.
46. Nonn L, Berggren M, and Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 1: 682-689, 2003.
47. Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, and Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci USA 99: 1259-1263, 2002.
48. Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, Shin SS, Choi YH, Park KJ, Park RW, and Hwang SC. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 11: 269-275, 2006.
49. Pervaiz S and Clement MV. Tumor intracellular redox status and drug resistance-serendipity or a causal relationship? Curr Pharm Des 10: 1969-1977, 2004.
50. Qi Y, Chiu JF, Wang L, Kwong DL, and He QY. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 5: 2960-2971, 2005.
51. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, and Lee SW. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231-234, 2011.
52. Rhee SG. H2O2, a necessary evil for cell signaling. Science 312: 1882-1883, 2006.
53. Rhee SG, Kang SW, Chang TS, Jeong W, and Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52: 35-41, 2001.
54. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, and Woo HA. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol 17: 183-189, 2005.
55. Rhee SG and Woo HA. Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H2O2, and protein chaperones. Antioxid Redox Signal 15: 781-794, 2011.
56. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
57. Sato K, Ito K, Kohara H, Yamaguchi Y, Adachi K, and Endo H. Negative regulation of catalase gene expression in hepatoma cells. Mol Cell Biol 12: 2525-2533, 1992.
58. Scaduto RC, Jr., and Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 76: 469-477, 1999.
59. Shen J, Person MD, Zhu J, Abbruzzese JL, and Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64: 9018-9026, 2004.
60. Stone JR and Yang SP. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 8: 243-270, 2006.
61. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, and Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 270: 296-299, 1995.
62. Szatrowski TP and Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798, 1991.
63. Tobiume K, Saitoh M, and Ichijo H. Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J Cell Physiol 191: 95-104, 2002.
64. Trachootham D, Alexandre J, and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
65. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, and Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by betaphenylethyl isothiocyanate. Cancer Cell 10: 241-252, 2006.
66. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, and Wahl GM. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044, 2002.
67. Veal E and Day A. Hydrogen peroxide as a signaling molecule. Antioxid Redox Signal 15: 147-151, 2011.
68. Veal EA, Day AM, and Morgan BA. Hydrogen peroxide sensing and signaling. Mol Cell 26: 1-14, 2007.
69. Wang T, Tamae D, LeBon T, Shively JE, Yen Y, and Li JJ. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 65: 10338-10346, 2005.
70. Weyemi U, Lagente-Chevallier O, Boufraqech M, Prenois F, Courtin F, Caillou B, Talbot M, Dardalhon M, Al Ghuzlan A, Bidart JM, Schlumberger M, and Dupuy C. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 31: 1117-1129, 2012.
71. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11: 3013-3069, 2009.
72. Woo HA, Kang SW, Kim HK, Yang KS, Chae HZ, and Rhee SG. Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfinic acid. Immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing sequence. J Biol Chem 278: 47361-47364, 2003.
73. Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, Omura K, Suzuki H, and Yoshida H. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 145: 127-132, 1999.
74. Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, Omura K, Harada H, Suzuki H, and Yoshida H. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 156: 27-35, 2000.
75. Yang KS, Kang SW, Woo HA, Hwang SC, Chae HZ, Kim K, and Rhee SG. Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid. J Biol Chem 277: 38029-38036, 2002.
76. Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB, Yu JH, Lim SP, Kim JM, and Jeon BH. Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung Cancer 60: 277-284, 2008.